Press Releases 2021PDF DOWNLOAD VIEW ALL NEWS
Leveljump Announces the Listing of its Common Share Purchase Warrants on the Venture Exchange
Toronto, ON – March 8, 2021 – LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that the Company has been granted approval by the TSX Venture Exchange (the "Exchange") for the listing of up to 10,507,663 Common Share Purchase Warrants (the "LevelJump Warrants"). The LevelJump Warrants are a supplemental listing to the LevelJump Common Shares under TSXV Policy 2.8 – Supplemental Listings.
As part of the Qualifying Transaction ("QT") between Good2Go2 Corp. and Canadian Teleradiology Services, Inc. ("CTS"), and the associated Concurrent Financing, the Company has issued 9,811,622 LevelJump Warrants to certain investors which will be eligible for listing on the Exchange. 8,978,289 warrants will be eligible for listing as of the date set by the Exchange (the "Warrant Listing Date"), while the remaining 833,333 warrants will be listed following the conclusion of certain imposed escrow conditions.
Further, an additional 696,041 LevelJump Warrants will be available for listing upon the exercise of certain options (the "Agent Options") granted to Mackie Research Capital Corporation, Canaccord Genuity Corp. and Industrial Alliance Securities Inc. (the "Agents") as compensation for their involvement in the issuance of subscriptions receipts by CTS under the Subscription Receipt Agreement.
Each LevelJump Warrant provides the holder with the option to purchase one (1) LevelJump Common Share at a price of $0.50, exercisable at any time prior to 5:00 p.m. (Toronto time) on December 14th, 2023 (36 months from the Listing Date of the LevelJump Common Shares).
The Company is excited to be able to offer increased liquidity to its warrant holders through this Supplemental Listing.
The Company would like to correct an item from its press release dated February 9, 2021, in that the 125,000 warrants being issued and mentioned in that press release were stated to have an exercise price of $0.45 per share when in fact the correct exercise price should read as $0.50 per share.
Additional information about the Company can be found by visiting the Company’s SEDAR profile at www.sedar.com.
About LevelJump Healthcare
Leveljump Healthcare Corp., (TSXV: JUMP) is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP plans to expand through the acquisition of independent healthcare facilities focused on diagnostic imaging as well as acquiring new disruptive imaging technologies.
ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.
Mitchell Geisler, Chief Executive Officer
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES